**Table 1. Distribution of genotypes and alleles rs4820293 and rs4820294 of the galectin-1 gene in the patients with colorectal cancer, N (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Genotypes and alleles** | **Groups of the study participants** | **χ2; p** | **OR [95% CI]** |
| **CRC patients** | **Healthy donors** |
| Single nucleotide polymorphism rs4820293 |
| AA | 16 (22.8) | 15 (21.4) | 0.534; 0.062 | 1.09 [0.49–2.41] |
| GG | 34 (48.6) | 31 (44.3) | 1.18 [0.61–2.31] |
| GA | 20 (28.6) | 24 (34.3) | 0.77 [0.38–1.56] |
| А | 26 (37.1) | 27 (38.6) | 0.030; 0.862 | 0.94 [0.47–1.86] |
| G | 44 (62.9) | 43 (61.4) |
| Single nucleotide polymorphism rs4820294 |
| GG | 32 (45.7) | 31 (44.3) | 0.189; 0.037 | 1.05 [0.54–2.06] |
| AA | 12 (17.1) | 14 (20.0) | 0.83 [0.35–1.94] |
| GA | 26 (37.2) | 25 (35.7) | 1.06 [0.53–2.11] |
| G | 45 (64.3) | 44 (62.9) | 0.031; 0.861 | 0.94 [0.47–1.87] |
| А | 25 (35.7) | 26 (37.1) |

χ2, Pearson's chi-square test; p, significance of the difference between the study groups; OR, odds ratio for the risk of the disease with 95% confidence interval (CI)

**Table 2. Distribution of genotypes and alleles rs4820293 and rs4820294 of the galectin-1 gene in the patients with colorectal cancer (patient numbers, N) depending on the clinical and morphological parameters of the tumor**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Single nucleotide polymorphism** | **Genotype** | **T1–2** | **T3–4** | **N0** | **N1–2** | **М0** | **M1** | **G1** | **G2** | **G3** |
| rs4820293 | AA | 5 | 11 | 10 | 9 | 12 | 2 | 5 | 19 | 2 |
| GG | 6 | 28 | 11 | 20 | 28 | 7 | 2 | 22 | 2 |
| GA | 4 | 16 | 4 | 16 | 18 | 3 | 4 | 11 | 3 |
| V; p | 0.133; 0.541 | 0.254; 0.104 | 0.076; 0.818 | 0.161; 0.458 |
| rs4820294 | GG | 5 | 27 | 6 | 29 | 26 | 6 | 5 | 9 | 6 |
| AA | 2 | 10 | 3 | 9 | 9 | 4 | 6 | 9 | 1 |
| GA | 8 | 18 | 16 | 7 | 23 | 2 | 0 | 34 | 0 |
| V; p | 0.175; 0.341 | 0.498; < 0.001 | 0.215; 0.199 | 0.455; < 0.001 |

V, Cramer's V criterion; p, significance of the association for nominal data

**Table 3. Tumor galectin-1 expression (% of the positive cells) in the patients with colorectal cancer depending on the genotypes of the gene galectin-1 polymorphisms**

|  |  |  |
| --- | --- | --- |
| **Single nucleotide polymorphism** | **Genotype** | **Galectin-1 positive tumor cells, Me [Q1; Q3], %** |
| rs4820293 | AA | 21 [5; 37] |
| GG | 22 [9; 56] |
| GA | 21 [2; 69] |
| rs4820294 | GG | 23 [7; 44] |
| AA | 20 [10; 51] |
| GA | 24 [9; 71] |

**Table 4. Plasma galectin-1 levels in the patients with colorectal cancer depending on the genotypes of the gene galectin-1 polymorphisms**

|  |  |  |
| --- | --- | --- |
| **Single nucleotide polymorphism** | **Genotype** | **Plasma galectin-1 levels, Me [Q1; Q3], ng/mL** |
| **CRC patients** | **Healthy donors** |
| rs4820293 | AA | 17.67 [14.37; 20.05] | 12.28 [12.26; 14.05] |
| GG | 16.21 [15.28; 18.72] | 13.63 [13.28; 14.45] |
| GA | 16.97 [14.57; 18.92] | 12.29 [12.23; 14.52] |
| rs4820294 | GG | 15.43 [12.23; 19.65] | 14.93 [12.78; 14.04]p1 = 0.030 |
| AA | 17.12 [13.45; 20.75] | 12.92 [12.89; 14.51]p2 = 0.040 |
| GA | 15.84 [14.65; 19.64] | 13.95 [13.92; 15.46] |

CRC, colorectal cancer

p1, significance of the difference with the parameter in the AA genotype carriers of the respective group; p2, significance of the difference with the similar genotype in the CRC patients